We are the first to test a JAK1/2 inhibitor in combination with a SOD mimetic in HGPS fibroblasts to target the mitochondrial dysfunction and reduce chronic inflammation in HGPS. This evidence concerns the gene JAK1 and Hutchinson-Gilford progeria syndrome.